C4 Therapeutics (CCCC) Preferred Stock Liabilities (2019 - 2020)
C4 Therapeutics' quarterly Preferred Stock Liabilities came in at $256.5 million in Q3 2020, up 25552.0% year-on-year from N/an in Q4 2019, and up 81.9% quarter-over-quarter from $141.0 million in Q2 2020.
C4 Therapeutics has reported Preferred Stock Liabilities for 2 years, with the latest figure at $256.5 million in Q3 2020.
- For the quarter ending Q3 2020, Preferred Stock Liabilities rose 25552.0% year-over-year to $256.5 million; the trailing twelve-month figure through Sep 2020 stood at $256.5 million (up 25552.0% YoY), and the FY2019 full-year result was $111.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q3 2020 stood at $256.5 million, up from $141.0 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $256.5 million in Q3 2020, with the low at $1.0 million in Q3 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | C4 Therapeutics | 561.03 Mn | 325.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 256.52 Mn |
| Jun 30, 2020 | 141.03 Mn |
| Dec 31, 2019 | 111.00 Mn |
| Sep 30, 2019 | 1.00 Mn |